期刊文献+

液相芯片技术在妇科肿瘤中的应用 被引量:1

Application of luminex technology in gynecological tumors
原文传递
导出
摘要 液相芯片技术作为新型生物分子检测技术,具有重复性好、灵活性好、灵敏度高等优点,可以简便、快速、经济地筛查正常组织与肿瘤组织基因及蛋白表达的差别,有助于研究妇科肿瘤发生、发展的分子机制,为妇科肿瘤的早期诊断和治疗提供新的途径。 Luminex technology, as a new type of biochip emerging, has many advantages, such as excellent repeatability, high flexibility, high sensitivity, etc. It can be used easily, quickly, economically to screen the gene and the protein expression changes, which contribute to the researches of molecular mechanisms involved in the development and progress of gynecological cancer and to provide new ways for the diagnosis and treatment of gynecological tumor.
作者 郑召玲 娄阁
出处 《国际肿瘤学杂志》 CAS 2013年第3期228-231,共4页 Journal of International Oncology
基金 基金项目:国家自然科学基金(81172453) 黑龙江省教育厅科技项目(12511239)
关键词 生殖器肿瘤 女(雌)性 液相芯片技术 Genital neoplasms, female Luminex technology
  • 相关文献

参考文献20

  • 1Xie C, Wang G. Development of simultaneous detection of total pros-tate-specific antigen (tPSA) and free PSA with rapid bead-based immunoassay. J Clin Lab Anal,2011,25( 1 ) :3742.
  • 2Arellano G, Hu S, Wang J, et al. Multiplexed immunobead-based assay for det- ection of oral cancer protein biomarkers in saliva. Oral Dis, 2008,14(8) :705-712.
  • 3Kim BK, Lee JW, Park PJ, et al. The multiplex bead array approach to identifying serum biomarkers associated with breast cancer. Breast Cancer Res,2009,11 (2) :R22.
  • 4Wu S, Zhu Z, He J, et al. A novel mutant-enriched liquidchip tech- nology for the qualitative detection of somatic mutations in KRAS gene from both serum and tissue samples. Clin Chem Lab Med, 2010,48 (8) :1103-1106.
  • 5Gu AD, Xie YB, Mo HY. Antibodies against Epstein-Barr virus gp78 antigen: a novel marker for serological diagnosis of nasopharyngeal carcinoma detected by xMAP technology. J Gen Virel, 2008, 89 (Pt 5) :1152-1158.
  • 6Mannarini L, Kratochvil V, Calabrese L, et al. Human Papilloma virus (HPV) in head and neck region : review of literature. Acta Oto- rhinolaryngol Ital, 2009,29 ( 3 ) : 119-126.
  • 7Su JH, Wu A, Scotney E, et al. Immunotherapyfor cervical cancer: Research status and clinical potential. BioDrugs, 2010,24 ( 2 ) : 109- 129.
  • 8Smith EM, Pawlita M, Rubenstein LM, et al. Risk factors and sur- vival by HPV-16 E6 and E7 antibody status in human papillomavirus positive head and neck cancer. Int J Cancer, 2010, 127 ( 1 ) : 111- 117.
  • 9Achour M, Zeghal D, Kochbati L, et al. Antibody response for L1, E6, E7 HPV 16, and HPV 18 antigens in Tunisian women with cervi- cal cancer. J Immunoassay Immunochem, 2009,30( 1 ) :82-96.
  • 10Ozaki S, Kitamura S, Hara H, et al. Clinical evaluation of a novel multiplex HPV genotyping reagent using the luminex xMAP technolo- gy. Rinsho Byori, 2012,60(7) :621-626.

同被引文献16

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部